AI’s Financial ROI in Payor UM: De-Risking Claims Denials

AI’s integration into healthcare payor operations isn’t just about small efficiency tweaks. It’s a complete overhaul of how utilization management (UM) and claims processing work. For payor-tech investors and policy analysts, figuring out this shift means getting into the weeds of the financial impact. You have to weigh the promise of lower administrative costs against the very real dangers of regulatory non-compliance and a bad reputation in the market. This article digs into the return on investment (ROI) for software sold to payors, especially tools targeting prior authorizations and claims denials.

Automated Prior Authorization: Where Efficiency and Cost-Cutting Meet

The paperwork and phone calls tied to prior authorizations have been a massive headache for everyone in healthcare for years. The American Medical Association (AMA) keeps pointing out how much time and money providers waste on this, with doctors and their teams burning an average of 13 hours a week on prior auths, pushing through about 39 requests for every single physician. For payors, that means huge operational costs. AI-powered software promises to clean up this mess, going from basic automation to smart decision support and even hands-off approvals for simple requests. The financial logic for a payor to buy in is hard to argue with. By automating the review of prior authorization requests that fit existing clinical guidelines, payors can slash the labor costs of manual review. This means reallocating skilled clinical staff, your nurses and doctors, to the complex cases that actually need a human brain. We’ve seen automated workflows cut the time spent on each request by 75%, and a small 10-provider practice can save an average of $126,000 a year in staff costs alone. The first win is an immediate drop in administrative spending which is a bottom-line metric for any payor. The real value, though, comes from faster decisions, which makes providers happier and (most importantly) gets members their care faster.

Working through the Regulatory Field: CMS Interoperability and Prior Authorization Rule

The efficiency gains are real, but the regulatory minefield is where investors can get blown up. The Centers for Medicare and Medicaid Services (CMS) Interoperability and Prior Authorization Rule (CMS-0057-F final rule) is completely changing the game. The rule started to take effect on January 1, 2026, forcing payors to give faster answers and provide specific reasons for any denial. Starting in March 2026, they also have to publicly report their prior authorization metrics. The big technical lift is the mandate for application programming interfaces (APIs) for prior auths, with a hard compliance date of January 1, 2027. And it doesn’t stop there. CMS has a proposed rule (CMS-0062-P) to apply many of these same requirements to prescription drugs. For AI vendors, this new rule creates both a huge opportunity and a serious threat. On one hand, the government forcing everyone to use electronic data exchange is perfect for AI tools that can read and process structured data way faster than a person. This regulatory push is practically a sales engine for AI-driven UM platforms. On the other hand, failing to comply brings heavy fines and a public relations disaster. Any AI tool sold to a payor has to prove it follows these rules to the letter, delivering not only speed but also a perfect audit trail and total transparency. So what does that mean for an investor? You have to grill a company on its regulatory roadmap. Demand to see proof of strong data governance, explainable AI, and a practical understanding of the law. A company that built its software using GMLP (Good Machine Learning Practice) from the start is going to be in a much better position to handle this.

Impact on Claims Denials: A Delicate Balance

The link between AI-driven prior auth and claims denials is complicated. In theory, a more efficient and accurate prior authorization process should mean fewer claims get denied later because of an authorization screw-up. If an AI approves a service based on clear criteria, the claim for that service shouldn’t get kicked back. Easy enough. But if it’s not managed carefully, rolling out AI in utilization management can actually make denial rates worse. Denial rates are already climbing, with recent data showing 41% of providers say more than 10% of their claims are denied, and the initial denial rate across the board was heading toward 11.8% in 2026. Hospital claim denials were already hovering near 12% in 2025. An AI algorithm that’s too aggressive, or one that wasn’t trained on enough real-world clinical examples, could just start denying more things upfront or endlessly asking for more information. That doesn’t solve the problem, it just shifts the administrative work back to the provider. For a payor, this is a major risk. Spiking denial rates lead to furious providers, angry members, and a spotlight from regulators. The real test for an AI vendor is building a system that balances efficiency with clinical common sense. This requires AI that has genuine clinical intelligence built in, not just a simple rules-based engine, to make decisions that have nuance. It needs to enable care, not just create a new digital roadblock.

Case Studies in Payor AI Adoption: UnitedHealth Group and Cohere Health

Looking at real-world examples gives us a good sense of where this is all going. UnitedHealth Group, a giant in the insurance world, is actively implementing AI to simplify how it runs. The company is putting serious money behind this, earmarking $1.5 billion for AI projects in 2026 alone, with a public goal to slash its prior authorization volume by 30% by the end of 2026 and process 80% of them instantly by the end of 2027. While they’re cagey about the specifics of their internal tech, their public reports clearly point to major investments in technology to drive down operating costs. Then you have a company like Cohere Health, which is a great example of a vendor selling clinical intelligence tools built specifically for the prior authorization mess. Cohere Health announced record growth in 2025 as it pushed its AI tools into new areas like inpatient care, payment integrity, and policy management. They’ve gotten noticed for it, landing on TIME’s World’s Top HealthTech Companies 2025 list and the 2026 Inc. 5000 list. More importantly, health plans using Cohere’s platform are reporting a 47% reduction in UM admin costs and an ROI as high as 9x. Cohere’s success is built on a digital platform that gets providers and payors working together, showing an AI-native way to fix a workflow disaster. Their whole business depends on delivering cost savings that payors can actually measure while also making the process better for providers and staying on the right side of the regulations. This focus on both operational wins and clinical quality is exactly what investors in this space should be looking for.

Investor Takeaways: De-risking AI Investments in Payor Workflows

For VCs looking at payor-tech, AI in utilization management offers a massive opportunity but comes with considerable risk. A company’s ROI is going to be determined by its ability to prove it can cut administrative costs, handle the complex CMS rules, and keep claims denial rates from going haywire. During due diligence, here’s what to focus on:

• Verifiable ROI: Does the solution deliver clear, provable administrative cost savings? Can you see the proof from a pilot or a current customer’s numbers?
• Regulatory Compliance: Is the company’s product roadmap built around the CMS deadlines for data exchange and transparency? Do they have a serious quality management system (like QMS / ISO 13485) in place or is it just talk?
• Clinical Efficacy and Provider Adoption: Does the AI actually help make better clinical decisions, or is it just a faster way to run a broken process? Check the provider adoption curve, if doctors hate using it, it’s a dead end.
• Data Moat and Algorithmic Durability: Does the company have a unique data advantage that lets them keep making their models smarter? What’s their plan for dealing with algorithmic drift so the AI’s performance doesn’t degrade over time?
• Scalability and Interoperability: Can this software actually plug into a payor’s existing (and often ancient) IT systems without a multi-year nightmare? Does it support the interoperability standards it needs to? Investing in AI for payor workflows demands that you understand the technology, the ugly details of healthcare finance, and the ever-changing regulatory environment. The companies that can show a clear path to making things more efficient, staying compliant, and getting payors and providers to work together are the ones that will secure funding and make a real impact.
  

  Methodology and Source Note

  We put this analysis together by reviewing public information, including policy documents from CMS, reports from groups like the American Medical Association, and general industry reporting on healthcare AI venture capital. The specific numbers on cost savings and denial rates come from aggregated industry reports and public financial statements from major payors where we could find them. Our comments on UnitedHealth Group and Cohere Health are based on their public statements, press releases, and their well-known positions in the market. All facts are tied to verified sources to give our audience a data-backed perspective.